{"id":"regadenoson-myocardial-perfusion-imaging","safety":{"commonSideEffects":[{"rate":"28","effect":"Dyspnea"},{"rate":"26","effect":"Chest discomfort"},{"rate":"24","effect":"Headache"},{"rate":"34","effect":"Flushing"},{"rate":"7","effect":"Palpitations"},{"rate":"12","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Regadenoson binds to adenosine A2A receptors on coronary vascular smooth muscle, causing vasodilation and increasing blood flow preferentially to normally perfused myocardium. This creates a differential in blood flow between healthy and ischemic regions, allowing visualization of perfusion defects on imaging. It is used as a pharmacologic stress agent as an alternative to exercise stress testing in myocardial perfusion imaging studies.","oneSentence":"Regadenoson is a selective adenosine A2A receptor agonist that increases coronary blood flow to detect areas of reduced perfusion during cardiac imaging.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:04.689Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myocardial perfusion imaging in patients unable to exercise or requiring pharmacologic stress testing"}]},"trialDetails":[{"nctId":"NCT06854458","phase":"NA","title":"The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-06-27","conditions":"Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow","enrollment":1000},{"nctId":"NCT06814587","phase":"","title":"Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-07-01","conditions":"Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)","enrollment":15},{"nctId":"NCT04316676","phase":"NA","title":"The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-06-16","conditions":"Coronary Artery Disease","enrollment":20},{"nctId":"NCT05583721","phase":"PHASE2","title":"Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-10-10","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT03102125","phase":"PHASE4","title":"Allograft Dysfunction in Heart Transplant","status":"RECRUITING","sponsor":"Paul Kim","startDate":"2019-10-01","conditions":"Heart Transplant Failure and Rejection","enrollment":376},{"nctId":"NCT00837369","phase":"PHASE1","title":"Regadenoson R-T Perfusion Imaging Trial","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2009-04-07","conditions":"Coronary Artery Disease, Myocardial Perfusion Abnormalities","enrollment":100},{"nctId":"NCT01334918","phase":"PHASE2","title":"A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-04-26","conditions":"Coronary Artery Disease (CAD)","enrollment":124},{"nctId":"NCT00826280","phase":"PHASE3","title":"Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-03-24","conditions":"Coronary Artery Disease (CAD)","enrollment":347},{"nctId":"NCT01489176","phase":"PHASE3","title":"Regadenoson Real Time Perfusion Imaging Trial-Optison","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2012-07-31","conditions":"Coronary Artery Disease, Myocardial Perfusion Abnormalities","enrollment":50},{"nctId":"NCT04465526","phase":"","title":"The Influence of Coronary Chronic Total Occlusion on Myocardial Perfusion on Computed Tomography","status":"COMPLETED","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2020-02-01","conditions":"Coronary Occlusion, Myocardial Ischemia, Myocardial Perfusion Imaging","enrollment":27},{"nctId":"NCT03354273","phase":"PHASE3","title":"An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2018-06-05","conditions":"Coronary Artery Disease (CAD)","enrollment":730},{"nctId":"NCT01250496","phase":"PHASE4","title":"Study With Aminophylline to Attenuate of the Side Effects of Regadenoson","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2010-11","conditions":"Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan","enrollment":248},{"nctId":"NCT03064295","phase":"","title":"Whole-Heart Myocardial Blood Flow Quantification Using MRI","status":"UNKNOWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-03-01","conditions":"Coronary Artery Disease, Coronary Microvascular Disease","enrollment":160},{"nctId":"NCT01336140","phase":"PHASE4","title":"Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2011-06","conditions":"Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson","enrollment":300},{"nctId":"NCT03800862","phase":"","title":"The Evaluation of the Roles of New Cardiac Imaging in Patients With Chest Pain","status":"TERMINATED","sponsor":"Lancaster General Hospital","startDate":"2019-03-27","conditions":"Cardiology, Radiology, Stenoses","enrollment":14},{"nctId":"NCT03449888","phase":"","title":"Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2018-07-01","conditions":"Veterans Referred to the St. Louis VAMC Stress Tes","enrollment":133},{"nctId":"NCT02749045","phase":"NA","title":"Simultaneous Assessment of FFR and SPECT","status":"TERMINATED","sponsor":"Prem Soman","startDate":"2016-07","conditions":"Coronary Artery Disease","enrollment":27},{"nctId":"NCT01655524","phase":"PHASE4","title":"The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2012-07","conditions":"Coronary Artery Disease","enrollment":""},{"nctId":"NCT01969916","phase":"NA","title":"Stress CT Perfusion in Patients With Chest Pain","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-06","conditions":"Coronary Artery Disease","enrollment":150},{"nctId":"NCT02589977","phase":"PHASE4","title":"Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF","status":"COMPLETED","sponsor":"Marvin W. Kronenberg, M.D.","startDate":"2015-11","conditions":"Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension","enrollment":55},{"nctId":"NCT02608944","phase":"NA","title":"Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging","status":"WITHDRAWN","sponsor":"University of Utah","startDate":"2012-09-30","conditions":"MRI Scans","enrollment":""},{"nctId":"NCT02697877","phase":"","title":"Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2016-02","conditions":"Coronary Artery Disease","enrollment":183},{"nctId":"NCT03917199","phase":"","title":"Utility of Regadenoson Low-dose Dynamic Computed Tomography for Myocardial Perfusion Assesment (ULYSSES Study).","status":"COMPLETED","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2016-11","conditions":"Myocardial Perfusion Imaging, Computed Tomography, Coronary Artery Disease","enrollment":60},{"nctId":"NCT01518777","phase":"NA","title":"Reducing Radioisotope Dose: the Half-Dose CZT Study","status":"COMPLETED","sponsor":"S.M.Chang, MD","startDate":"2012-01","conditions":"Coronary Artery Disease","enrollment":74},{"nctId":"NCT01655043","phase":"PHASE2","title":"Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2012-09","conditions":"Myocardial Ischemia","enrollment":20},{"nctId":"NCT03976921","phase":"NA","title":"Impact of Stress CT Myocardial Perfusion on Downstream Resources and Prognosis","status":"UNKNOWN","sponsor":"Centro Cardiologico Monzino","startDate":"2019-06-01","conditions":"Coronary Artery Disease, Myocardial Ischemia","enrollment":2000},{"nctId":"NCT02560467","phase":"NA","title":"Perfusion Imaging With Myocardial Contrast Echocardiography in HCM","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2015-12-01","conditions":"Hypertrophic Cardiomyopathy","enrollment":10},{"nctId":"NCT02115308","phase":"PHASE4","title":"Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"Timothy M. Bateman","startDate":"2014-09-03","conditions":"Coronary Artery Disease","enrollment":40},{"nctId":"NCT01949844","phase":"NA","title":"Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies","status":"COMPLETED","sponsor":"Daniel S. Berman","startDate":"2014-05-16","conditions":"Coronary Artery Disease, CAD","enrollment":44},{"nctId":"NCT01919450","phase":"PHASE4","title":"Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation","status":"COMPLETED","sponsor":"Timothy M. Bateman, MD","startDate":"2013-07","conditions":"Myocardial Blood Flow Reserve","enrollment":80},{"nctId":"NCT01779869","phase":"PHASE4","title":"Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-01","conditions":"Ischemic Heart Disease","enrollment":16},{"nctId":"NCT03084562","phase":"","title":"Regadenoson vs Dipyridamole in Use as Pharmacological Stress Agent Before SPECT","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2017-05-03","conditions":"Myocardial Perfusion Imaging","enrollment":300},{"nctId":"NCT01788631","phase":"PHASE2","title":"A Phase II Trial of Regadenoson in Sickle Cell Anemia","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-07","conditions":"Sickle Cell Anemia","enrollment":100},{"nctId":"NCT02597543","phase":"PHASE4","title":"Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction","status":"COMPLETED","sponsor":"Paul Kim","startDate":"2015-11","conditions":"Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection","enrollment":14},{"nctId":"NCT02628002","phase":"NA","title":"Anti-gravity Treadmill Exercise in Stress Myocardial Perfusion Imaging","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2015-12","conditions":"Coronary Artery Disease","enrollment":49},{"nctId":"NCT01618669","phase":"PHASE3","title":"A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-06","conditions":"Coronary Artery Disease (CAD)","enrollment":1147},{"nctId":"NCT01019486","phase":"PHASE4","title":"Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2009-11","conditions":"Coronary Artery Disease, Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT01150578","phase":"","title":"Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography","status":"UNKNOWN","sponsor":"Aiden Abidov","startDate":"2011-12","conditions":"Myocardial Ischemia","enrollment":380},{"nctId":"NCT01697995","phase":"","title":"Stress Induced Right Ventricular Uptake on Lexiscan Stress MPI","status":"UNKNOWN","sponsor":"Aiden Abidov","startDate":"2013-01","conditions":"Increased Right Ventricular Radiotracer Uptake","enrollment":650},{"nctId":"NCT01370265","phase":"NA","title":"Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-02","conditions":"Coronary Artery Disease","enrollment":12},{"nctId":"NCT01021618","phase":"NA","title":"Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging","status":"COMPLETED","sponsor":"Hartford Hospital","startDate":"2010-01","conditions":"Coronary Artery Disease, Myocardial Ischemia","enrollment":140},{"nctId":"NCT00808314","phase":"PHASE4","title":"Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress","status":"UNKNOWN","sponsor":"Cardiovascular Imaging Technologies","startDate":"2008-12","conditions":"Coronary Artery Disease","enrollment":32},{"nctId":"NCT00881218","phase":"EARLY_PHASE1","title":"Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-06","conditions":"Ischemic Heart Disease","enrollment":50},{"nctId":"NCT00859833","phase":"NA","title":"Effects of Body Mass Index on the Hyperemic Response to Regadenoson","status":"COMPLETED","sponsor":"University of Utah","startDate":"2009-02","conditions":"Obesity, Endothelial Dysfunction, Decreased Vascular Flow","enrollment":30},{"nctId":"NCT00208299","phase":"PHASE3","title":"ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-10","conditions":"Coronary Artery Disease","enrollment":1231},{"nctId":"NCT00208312","phase":"PHASE3","title":"ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2004-04","conditions":"Coronary Artery Disease","enrollment":787}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":232,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cardiolite (sestamibi)","Regadenoson (Lexiscan)"],"phase":"marketed","status":"active","brandName":"Regadenoson myocardial perfusion imaging","genericName":"Regadenoson myocardial perfusion imaging","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Regadenoson is a selective adenosine A2A receptor agonist that increases coronary blood flow to detect areas of reduced perfusion during cardiac imaging. Used for Myocardial perfusion imaging in patients unable to exercise or requiring pharmacologic stress testing.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}